CordenPharma has expanded its peptide manufacturing capacity in CordenPharma Colorado, their GMP API facility in Boulder, Colorado. The expansion was done in order to accommodate for a large spike in demand for peptide API’s and to continue an overall growth strategy.
 
Dr. Matthieu Giraud, director, Global Peptides, Lipids & Carbohydrates Platform, explained, “With the addition of this extra-large 3’000 L SPPS vessel, our assembly-time, capacity and flexibility has been significantly increased, reinforcing CordenPharma Colorado as the current large-scale peptide manufacturing capacity leader. This new asset gives us the ability to manufacture a complex long peptide with a 400 kg output per single batch. Our team in Colorado aims to utilize this new capacity to conduct validation campaigns designed to support customer projects with a global impact.”
 
With approximately 300 employees, CordenPharma Colorado has a long track record in large-scale manufacturing, where all potencies, including picogram levels, can be reached.